Blood Test Rapidly Identifies Low Risk of Cardiac Event
By LabMedica International staff writers Posted on 21 Oct 2015 |
A test that measures blood for the cardiac troponin protein, which is released by damaged heart cells, may help doctors rule out heart attack faster in patients with similar symptoms.
Suspected acute coronary syndrome is the most common reason for emergency admission to hospital and is a large burden on health-care resources and strategies to identify low-risk patients suitable for immediate discharge would have major benefits.
Medical scientists at the University of Edinburgh (UK) consecutively enrolled 6,304 patients with suspected acute coronary syndrome presenting to four secondary and tertiary care hospitals in Scotland in a prospective cohort study. They assessed the threshold of cardiac troponin in two independent validation cohorts. The first validation cohort included 1,126 consecutively enrolled patients with suspected acute coronary syndrome and the second included 308 consecutively enrolled patients at a different medical center.
As standard of care, a sensitive cardiac troponin I assay (ARCHITECTSTAT troponin I assay; Abbott Laboratories, Abbott Park, IL, USA) was used for clinical decision making and the result declared to the patients' clinicians. The assay has a limit of detection of 1.2 ng/L, and an upper reference limit (99th centile) of 34 ng/L in men and 16 ng/L in women. In derivation and validation cohorts, they evaluated the negative predictive value of a range of troponin concentrations for the primary outcome of index myocardial infarction, or subsequent myocardial infarction or cardiac death at 30 days.
The investigators found that 782 of 4,870 (16%) patients in the derivation cohort had index myocardial infarction, with a further 32 (1%) re-presenting with myocardial infarction and 75 (2%) cardiac deaths at 30 days. In patients without myocardial infarction at presentation, troponin concentrations were less than 5 ng/L in 2,311 of 3,799 (61%) patients, with a negative predictive value of 99.6% for the primary outcome. In two independent validation cohorts, troponin concentrations were less than 5 ng/L in 594 of 1,061 (56%) patients, with an overall negative predictive value of 99.4%. At one year, these patients had a lower risk of myocardial infarction and cardiac death than did those with a troponin concentration of 5 ng/L or more.
The authors concluded that low plasma troponin concentrations identified two-thirds of patients at very low risk of cardiac events who could be discharged from hospital. Implementation of this approach could substantially reduce hospital admissions and have major benefits for both patients and health-care providers. The study was published on October 7, 2015, in the journal the Lancet.
Related Links:
University of Edinburgh
Abbott Laboratories
Suspected acute coronary syndrome is the most common reason for emergency admission to hospital and is a large burden on health-care resources and strategies to identify low-risk patients suitable for immediate discharge would have major benefits.
Medical scientists at the University of Edinburgh (UK) consecutively enrolled 6,304 patients with suspected acute coronary syndrome presenting to four secondary and tertiary care hospitals in Scotland in a prospective cohort study. They assessed the threshold of cardiac troponin in two independent validation cohorts. The first validation cohort included 1,126 consecutively enrolled patients with suspected acute coronary syndrome and the second included 308 consecutively enrolled patients at a different medical center.
As standard of care, a sensitive cardiac troponin I assay (ARCHITECTSTAT troponin I assay; Abbott Laboratories, Abbott Park, IL, USA) was used for clinical decision making and the result declared to the patients' clinicians. The assay has a limit of detection of 1.2 ng/L, and an upper reference limit (99th centile) of 34 ng/L in men and 16 ng/L in women. In derivation and validation cohorts, they evaluated the negative predictive value of a range of troponin concentrations for the primary outcome of index myocardial infarction, or subsequent myocardial infarction or cardiac death at 30 days.
The investigators found that 782 of 4,870 (16%) patients in the derivation cohort had index myocardial infarction, with a further 32 (1%) re-presenting with myocardial infarction and 75 (2%) cardiac deaths at 30 days. In patients without myocardial infarction at presentation, troponin concentrations were less than 5 ng/L in 2,311 of 3,799 (61%) patients, with a negative predictive value of 99.6% for the primary outcome. In two independent validation cohorts, troponin concentrations were less than 5 ng/L in 594 of 1,061 (56%) patients, with an overall negative predictive value of 99.4%. At one year, these patients had a lower risk of myocardial infarction and cardiac death than did those with a troponin concentration of 5 ng/L or more.
The authors concluded that low plasma troponin concentrations identified two-thirds of patients at very low risk of cardiac events who could be discharged from hospital. Implementation of this approach could substantially reduce hospital admissions and have major benefits for both patients and health-care providers. The study was published on October 7, 2015, in the journal the Lancet.
Related Links:
University of Edinburgh
Abbott Laboratories
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines